Results
At 28 weeks, women in the intervention arm showed a mean of 1213 kCal (standard deviation [SD] 931) exercise per week compared with 710 kCal (SD 873) for the control group (P ¼ 0.03). However, there was no statistically significant difference in the overall physical activity of the two groups. On objective measure with the accelerometer, there was no difference in physical activity in either group at any point during pregnancy.
Discussion
Despite the intensive efforts to assist women to exercise in this study, there was no objective evidence that an exercise programme of this type succeeded in providing women with a 'dose' of exercise. There was an interesting difference between the results of the validated pregnancy physical activity questionnaire and objective accelerometer measurements. This highly supported, individualized exercise intervention is not a feasible way of increasing exercise in obese pregnant women. (DOI: 10.1258 (DOI: 10. /om.2008 Thrombosis/thrombophilias and adverse pregnancy outcomes Background Pregnancy for women with mechanical heart valves presents a challenging dilemma. Warfarin is the preferred option for maternal health, but for the fetus anticoagulation that does not cross the placenta, such as enoxaparin, is preferable.
Aim
To determine the efficacy and safety of enoxaparin in women with mechanical heart valves during pregnancy.
Methods
Pregnancy outcome data were collated on a prospective (1997) (1998) (1999) (2000) (2001) (2002) (2003) (2004) (2005) (2006) (2007) (2008) cohort of women with mechanical heart valves managed with enoxaparin + aspirin. Women were classified as: group 1 enoxaparin commenced by six weeks gestation and continued through pregnancy; group 2 enoxaparin commenced 7-19 weeks; group 3 warfarin ! enoxaparin (6-14 weeks) ! warfarin or warfarin !enoxaparin ! 34 weeks.
Results
Forty-five pregnancies in 30 women (Table 1) ; there were no thrombotic complications in group 1 and four in group 2 (one on enoxaparin, 2 on enoxaparin started after no anticoagulation for months and one on subtherapeutic unfractionated heparin). One woman in group 3 had a CVA at 13 weeks on subtherapeutic enoxaparin. The thromboembolic rate was one per 80 enoxaparin-prescribed months. Among pregnancies continuing after 12 weeks, all 14 (100%) in group 1 resulted in livebirths, in group 2 there was one perinatal death following spontaneous premature birth and 10 (92%) livebirths, and in group 3 there were three late pregnancy losses, one neonatal death attributable to warfarin and seven (64%) healthy live babies.
Conclusion
Successful pregnancy can be achieved with therapeutic-dose enoxaparin, with enoxaparin-attributable thrombotic complications in 4.4% of pregnancies and haemorrhagic complications in 17.8%.
Background
Pregnant women with antiphospholipid syndrome (APS) may have adverse maternal and fetal outcomes; treatment with aspirin + low-molecular-weight heparin (LMWH) reduces the risk of adverse outcomes. Systematic review has shown that women with previous thromboembolic events have worse pregnancy outcomes than those with other forms of APS.
Objectives
To assess pregnancy outcome in women with APS treated with aspirin + LMWH within a multidisciplinary specialized clinic and according to an agreed protocol. To determine whether previous thromboembolism is associated with increased risk of adverse events. 
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Design
Retrospective analysis of 91 pregnancies in women with a diagnosis of APS made prior to pregnancy.
Results
The pregnancy outcome of these women is shown in the 
Conclusion
Women with APS have good outcomes in pregnancy when treated with aspirin + LMWH within a specialized clinic. Women with previous thromboembolism have significantly higher rates of preeclampsia and small for gestational age (SGA) babies than women without previous thromboembolic events. Women with recurrent miscarriages had significantly higher rates of SGA than women with adverse obstetric histories.
What is the best imaging of lower-limb venous thromboembolism in pregnancy? Venous thromboembolism (VTE) remains a leading cause of maternal mortality. Doppler-ultrasound is the most convenient and accepted first-line imaging for lower-limb VTE. We report three cases where repeated Doppler-ultrasound was negative, but magnetic resonance imaging (MRI) confirmed the high clinical suspicion of VTE. A 32-year-old P0 at 22/40 gestation presented with left leg swelling, Doppler-ultrasound found no evidence of VTE. She represented with left-sided back pain radiating down the leg. A second Doppler-ultrasound was inconclusive. MRI-scan confirmed an external and common left iliac vein thrombus.
A 33-year-old P0 presented at 28/40 gestation with back pain. Doppler-ultrasound showed no evidence of VTE. She represented with left leg swelling. Again a Doppler-ultrasound was negative. She represented with increased left leg pain and a further Dopplerultrasound was negative. MRI-scan confirmed .8 cm thrombus in the left common iliac vein extending to the left external iliac vein.
A 30-year-old P0 presented at 33/40 gestation with left leg swelling. Doppler-ultrasound showed no evidence of VTE. She represented on two further occasions with increased left leg pain and on both occasions Doppler-ultrasound was negative. MRI-scan confirmed expansion and thrombosis of the left femoral vein extending into the pelvis and occluding the left common iliac vein.
These cases highlight the importance of further imaging for lower-limb VTE where the index of suspicion remains high and, though none had any family or personal history of VTE, one case was later found to be lupus-coagulant positive and the other had a rare congenital vascular anomaly. This study aimed to define the contribution of maternal medical disorders to stillbirth.
Medical antecedents of stillbirth in Western Australia
In 2000-2001, stillbirths after 31 weeks gestation, and in 2002-2006, the majority after 25 weeks were examined in detail by one of three appointed medical investigators given full access to case-notes and empowered to make further enquiries of treating clinicians. Othercases were coded using limited clinical information (death certificates, midwifery notification forms and autopsy results).
Results
There were 180,808 livebirths and 1327 stillbirths in WA in 2000-2006 (7.3/1000 births). The hierarchical PSANZ PDC requires one 'principal diagnosis code'. By this system, maternal medical disorders were judged the primary cause of stillbirth in 229 cases (17.3%; 1.3/1000 births), comprising 99 due to antepartum haemorrhage, mostly abruption (7.5%), 74 to hypertension (including preeclampsia and HELLP syndrome 5.6%), 33 to diabetes mellitus (2.5%) and 23 due to 'other maternal conditions', including SLE and thrombotic disorders (1.7%). In no case was stillbirth attributed to cholestasis of pregnancy. Further, 27.5% were due to congenital abnormality, 19.5% had no cause found, 12.3% were due to spontaneous preterm birth, 9.1% were attributed to a specific perinatal condition, 6.7% to fetal growth restriction and 4.5% to perinatal infection.
Conclusion
Using the 'single diagnosis' PSANZ PDC, 17.3% of stillbirths in WA were attributed to maternal medical disorders. 
Aim
To study the risk factors for venous thromboembolism in pregnant Singaporean women and the outcomes of treatment.
Methods
This was a retrospective study based on data collected from the medical records of 20 pregnant women with objectively confirmed deep vein thrombosis (DVT)/pulmonary embolism (PE) 1999-2007.
Results
Of the 20 pregnant women with DVT/PE, 14 (70%) were Chinese, four of 20% were Malay and one (5%) Indian. One woman had previous history of DVT and two had positive family history. Eighteen (90%) women presented antenatally and two of 10% presented postnatally. The majority (17) presented with DVT ( predominantly in the left lower limb) and were treated with subcutaneous low-molecular-weight heparin (LMWH). Four women presented with PE-two of whom were treated with thrombolytic, one with intravenous heparin and one with emergency embolectomy. Complications of treatment with LMWH included cutaneous hypersensitivity reaction and osteopaenia. Pregnancy loss occurred in one woman treated with streptokinase and maternal death in the patient who underwent emergency embolectomy. Identified risk factors included age . 35 years, multiparity, obesity, hyperemesis, ovarian hyperstimulation syndrome, prolonged bed rest, air travel and the presence of thrombophilia. There is a substantial variation in the reported rates of venous thromboembolism (VTE) in pregnancy. Much of the data antedate the use of specific thromboprophylaxis following caesarean section, which was introduced in the UK in 1996. This study aimed to describe the pattern of VTE in pregnancy in the Scottish Population between 1980 and 2005, and identify any temporal relationship with the introduction of routine thromboprophylaxis.
Conclusion
Data were extracted from the Scottish Morbidity Record, a registry of patient characteristics and outcomes for all patients discharged from Scottish hospitals. Crude and adjusted odds ratios (aOR) for each outcome of VTE during pregnancy were obtained by logistic-regression analysis. The mother's age, time period of admission, parity, previous diagnosis of VTE, mode of delivery, smoking, deprivation, antepartum haemorrhage and abruption, postpartum haemorrhage, any haemorrhage, preeclampsia and hypertension were treated categorically in logistic-regression models ( Table 1 ). The total number of maternities was 1,550,286 between 1980 and 2005. The overall rate of VTE was 1.399/1000. As thromboprophylaxis was introduced in 1996 for caesarean section, logistic regression was performed for caesarean sections only and the OR for the period 1996-2005 versus 1980-1995 was 0.7 (95% confidence interval [0.5-1.0; P ¼ 0.035]).
These data support and quantify known risk factors and the temporal relationship, showing a reduction in risk in recent years, raises the possibility of benefit from routine thromboprophylaxis.
Iliac vein compression during twin gestation: a case report
Meghan Hayes MD, Ghada Bourjeily MD, Courtney A Woodfield MD and Lucia Larson MD Women and Infants' Hospital and Rhode Island Hospital, The Warren Alpert Medical School of Brown University, Providence, USA A 30-year-old gravida 2 para 1001 at 26 weeks with twins presented with one day of severe left pelvic pain without dyspnoea, chest discomfort or leg oedema (Figures 1 and 2) . She was a healthy nonsmoker without recent travel, personal or family history of venous thromboembolism. Examination revealed prominent left vaginal varicosities. Magnetic resonance venogram (MRV) of her pelvis without gadolinium showed complete extrinsic compression of the left common iliac vein (LCIV) without demonstrable flow or visualized thrombus. Bilateral leg ultrasound was negative. Thromboprophylaxis with low-molecular-weight-heparin (LMWH) was initiated. Pelvic pain resolved. Repeat pelvic MRV in two weeks again found no LCIV flow and new LCIV expansion suggesting interval intraluminal thrombus. Therapeutic anticoagulation with LMWH commenced. She delivered vaginally at 36 weeks, induced for growth restriction of twin A, female, 2350 g 
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with activity, pulse, grimace, appearance, and respiration (APGAR) 9 and 9; twin B was male, 3090 g with APGAR 9 and 9. Therapeutic LMWH was resumed postpartum. Dilatation and curettage were performed postpartum day 11 for retained products of conception and persistent vaginal bleeding. She was then transitioned to warfarin, to complete six months total anticoagulation. Repeat pelvic MRV six weeks postpartum (Figures 3 and 4 ) showed left internal iliac vein (LIIV) occluded 1 cm beyond its origin without acute thrombosis. Repeat pelvic MRV and magnetic resonance angiogram with gadolinium performed six months after the first study showed stable LIIV chronic occlusion and mild LCIV extrinsic compression by right common iliac artery (anatomic variant known as May-Thurner syndrome). Thrombophilia evaluation was unrevealing. As the patient remained asymptomatic, further intervention was deferred.
Preeclampsia a prelude to cerebral venous thrombosis
Nageena Mahmood
Corniche Hospital, Abu Dhabi, UAE
Background
Cerebral venous thrombosis is usually seen postnatally in patients with an underlying thrombophilia, no relationship with preeclampsia has previously been reported.
Case 1
A 32-year-old Indian lady who had preeclampsia in her second pregnancy, delivered at term by a vaginal delivery. She was discharged on day five postnatally, re-admitted on day 15 with headache, vomiting and seizures. Cerebral venous thrombosis was diagnosed on computed tomography (CT) brain and anticoagulation commenced.
Case 2
A 32-year-old Mexican-American had four uneventful pregnancies with her first husband. She then had severe early onset preeclampsia in the first pregnancy with her second husband. Had induction of labour and delivered vaginally at 35 weeks gestation. On the second day postnatally, she had severe headache that did not respond to analgesia. Presented to hospital on day 15 with severe headache, right-sided hemiplegia and aphasia, later had seizures. CT revealed an extensive superior sagittal thrombosis with extension into the internal jugular vein.
Commenced on enoxaparin and later warfarin.
Case 3
A 30-year-old Indian lady who developed severe early-onset preeclampsia with intrauterine growth restriction requiring termination of pregnancy at 29 weeks of gestation by caesarean section. Presented on day 21 with severe occipital headache and hallucinations, CT scan showed partial occlusion of the 
Conclusion
In all three patients, the thrombophilia screen was negative, but a history of preeclampsia in the index pregnancy was elicited.
Introduction
Formerly preeclamptic women are at increased risk of venous thromboembolism. This study was designed to determine the prevalences of acquired and inherited thrombophilia disorders in different clinical subtypes of preeclampsia (PE). 
Methods
Conclusion
The prevalences of acquired and inherited thrombophilic disorders were higher in women after severe PE and women after early-onset PE. In particular, in women after severe PE in combination with only IUGR, the prevalence of thrombophilic disorders was higher than after severe PE in combination with HELLP without IUGR. 
Thrombophilia and pregnancy complications: maternal and fetal outcomes
Objectives
To determine genetic thrombophilia, and to evaluate maternal and fetal outcomes in women with history of pregnancy complications receiving preconception treatment.
Material and methods
One hundred and fifty patients with fetal loss syndrome, 56 patients with preeclampsia, 37 patients with venous thromboembolism (VTE), 46 patients with placental abruption and 150 healthy controls were tested to have genetic thrombophilia and antiphospholipid antibodies. Women with a history of pregnancy complications received treatment in the preconception period and during pregnancy, including low-molecular-weight heparin (LMWH) guided by D-dimer, aspirin in low doses, antioxidants, vitamins of B group, folic acid (up to 4 mg in women with hyperhomocysteinaemia and MTHRR C677T).
Results
Thrombophilia was found in 82% women with fetal loss syndrome, in 96.4% women with recurrent preeclampsia and in 100% women with placental abruption and VTE. In women with fetal loss syndrome methylenetetrahydrofolate reductase (MTHFR) C667T, anticardiolipin antibodies, FV Leiden, prothrombin G20210A, multigenic thrombophilia were found in 41.3%, 29.3%, 15.3%, 4% and 20% respectively; in women with preeclampsia, in 44.6%, 16%, 17.8%, 3.6% and 73.2%; in women with placental abruption and VTE in 71%, 25.3%, 25.3%, 37.4% and 96.4%; and in controls in 12%, 4%, 2%, 1.3% and 4% respectively. Prevalence of thrombophilias in study group was higher versus controls (P , 0.05). In the study group nobody had moderate or severe form of preeclampsia, mild preeclampsia was observed in 16%, all babies were alive. Preconception therapy allowed preventing recurrent fetal loss syndrome in 66%; 96% patients were delivered after 37 weeks. Patients did not have recurrence of placental abruption or VTE and all babies were alive.
Conclusion
Thrombophilia might be the main pathogenetic mechanism of recurrent pregnancy complications. Due to thrombophilia involvement in trophoblast invasion and placentation, early treatment is essential. Preconception treatment with LMWH, antioxidants and vitamins allows preventing recurrent pregnancy complications and fetal losses in most cases.
Low-molecular-weight heparin versus no treatment in women with previous severe preeclampsia, FGR <5th percentile, severe placental abruption, stillbirth >20 weeks inherited thrombophilia: a retrospective study 
Objectives
To investigate the effect of low-molecular-weight heparin (LMWH) on adverse outcome in women with thrombophilia and severe pregnancy complications.
Methods
The study included 116 women with history of severe preeclampsia (PET), fetal growth restriction (FGR) 5th percentile, severe placental abruption and stillbirth .20 weeks who delivered between the years 2001 and 2006 in our institution, and in whom factor V Leiden or prothrombin mutation or protein S or protein C deficiency were found. All women were referred to our outpatient clinic or for delivery. Our policy is to treat women with previous severe pregnancy complications and thrombophilia with LMWH (enoxaparin) in the following pregnancy. Therefore, women referred to us for follow-up were treated with LMWH starting from weeks 5-15. Women who were referred after 15 weeks were treated, but excluded from the study. Women who were treated with low-dose aspirin were also excluded.
Results
Eighty-seven were treated with LMWH (group A). Twenty-nine women were followed elsewhere and were not treated and were referred only for delivery in our institution (group B). The incidence of severe PET, FGR, stillbirth and placental abruption in previous pregnancies was similar in groups A and B. The incidence of severe PET in the treated group (A) was 4.6% compared with the non-treated group (B) 21%, P ¼ 0.007. Similarly, the incidence of FGR was 2.3% in group A compared with 21% in group B, P ¼ 0.03. The incidence of stillbirth or placental abruption was 0% in group A compared wtih 7% in group B, P ¼ 0.06 for both. The þtotal incidence of adverse outcome was 7% in group A compared with 55% in group B, P ¼ 0.0001.
Conclusion
In women with severe pregnancy complications and thrombophilias, treatment with LMWH dramatically reduces the rate of recurrence.
Thromboelastometry as an adjunctive test in thrombophilia screening for adverse pregnancy outcome 
Objectives
Thrombophilia has been associated with adverse pregnancy outcome. Thromboelastometry is an easy, rapid and reproducible test that offers the opportunity to investigate all phases of coagulation and fibrinolysis in whole blood. The purpose of this study was to determine if an additional group of women with coagulopathy could be found with the use of thromboelastometry, that are not yet identified with routine thrombophilia screening and that are at risk of adverse pregnancy outcome.
Study design
Included were women that had been referred for routine thrombophilia screening because of their complicated obstetric histories. The routine thrombophilia screening includes testing for protein S, protein C, antithrombin III, activated-protein C resistance, factor V Leiden, prothrombin mutation, antiphospholipid antibodies and methionine loading testing. 
Results
Eighty-four non-pregnant women with a history of previous severe preeclampsia, Hemolysis, elevated liver function, low platelets (HELLP) syndrome, intrauterine growth restriction, placental abruption, fetal loss and recurrent miscarriage were included. In 27 (31%) women, thrombophilia was diagnosed by routine testing; in this group, 15 women also had abnormal thromboelastometry. In 57 women, no thrombophilia was found; in this group, 32 women had an abnormal thromboelastometry.
Conclusion
Thromboelastrometry does detect a group of women with abnormal coagulation that are not detected by routine thrombophilia screening. Additional studies are warranted to determine if thromboelastometry identifies a subset of women with a prothrombotic tendency that are at an increased risk of recurrent adverse pregnancy outcome. 
Objectives
Preeclampsia and cardiovascular disease share many risk factors, and women with preeclampsia are at increased risk of cardiovascular mortality later in life. We investigated whether risk factors associated with cardiovascular disease and preeclampsia remain elevated months postpartum.
Methods
WemeasuredplasmasolubleFMSliketyrosinekinase1(sFlt1),endoglin, placental growth factor (PlGF), cellular fibronectin (cFN), uric acid, homocysteine and asymmetric dimethylarginine (ADMA) in 30 women with uncomplicated normotensive pregnancies compared with 20 women with preeclampsia in samples collected at predelivery and again several months postpartum (average 10.6 + 6.2 months). Data were mean + SD or median (interquartile range). Statistical analysis was by Wilcoxon rank-sum or Student's unpaired t-tests with statistical significance accepted at P , 0.05.
Results
The mean concentrations of sFlt1, endoglin, PlGF, homocysteine, ADMA, cFN and uric acid was all significantly different in samples collected predelivery in subjects with preeclampsia compared with controls (P , 0.05). ADMA (0.67 + 0.17 versus 0.53 + 0.09 mM), cFN (43.8 + 26.1 versus 30.3 + 17.1 mg/mL) and uric acid (5.3 + 0.8 versus 4.5 + 1.2 mg/dL) remained significantly higher postpartum in subjects with previous preeclampsia compared with postpartum controls (respectively).
Conclusion
Biological markers associated with altered vascular function or cardiovascular risk are elevated in women with preeclampsia and some remain significantly higher in postpartum preeclamptic women. These data suggest that vascular dysfunction persists in women with previous preeclampsia and may contribute to the increased risk of future cardiovascular disease. 
Objectives
To determine the prevalence of risk factors for cardiovascular disease in women with preeclampsia (PE).
Methods
Forty women with PE and 14 normotensive pregnant women treated 10 or more years before at Hospital de Clínicas de Porto Alegre were submitted to clinical and laboratorial exams.
Results
Patients with PE for 10 or more years had significantly higher diastolic blood pressure (P ¼ 0.047), body mass index (BMI) (P ¼ 0.019) and abdominal circumference (P ¼ 0.026) than the control group. The group of patients with PE presented positive correlations between BMI and diastolic blood pressure (BP [0.341, P ¼ 0.031]) and systolic BP (0.407, P ¼ 0.009).
Conclusion
Patients with PE for 10 or more years presented significantly higher diastolic BP, BMI and abdominal circumference measurements than those in the control group. This emphasizes the importance of long-term follow-up assessment for cardiovascular risk factors in patients with previous PE.
Angiotensin receptor agonistic autoantibodies from preeclamptic patients pass through placenta and affect the fetal development
